A Retrospective Study Comparing the Clinical Benefits of Combination of Stereotactic body radiation therapy (SBRT) with Sorafenib Versus Stereotactic Body Radiation Therapy (SBRT) Alone in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Latest Information Update: 28 Apr 2020
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 28 Apr 2020 New trial record
- 01 Mar 2020 Results published in the Medicine